PCI Pharma Services expands serialisation capacity

Outsourcing services provider PCI Pharma Services (PCI) has significantly expanded its serialisation capability.

PCI will bolster its capacity across its global supply network to support clients in advance of meeting both US DSCSA and EU FMD implementation dates.

The company has been actively serialising commercial products for both domestic and international markets for the past five years, with products destined for North America and Europe, in addition to emerging market geographies such as South Korea, Turkey, Brazil, China and others. In total, PCI supports medicines destined to over 100 global countries.

This latest expansion triples the company’s its global serialisation capacity in advance of upcoming DSCSA and FMD requirements.

As part of the latest installation, PCI has partnered with Antares Vision, Marchesini and Domino.

The multi-site installations support a variety of drug delivery forms, including bottles, unit cartons and parenteral kits, as well as unit dose wallets and child resistant/compliance prompting packaging.

In addition, serialisation technologies support ancillary and tertiary packaging, corrugated shippers and palletisation solutions for supporting multi-level product aggregation.

Ken Richardson, Vice President of Global Engineering, said: “This latest investment is considerable, and features what we believe are truly industry-leading technologies. The spotlight is on the industry to meet the November deadline and PCI has directed an amazing amount of financial resource, technological expertise and manpower to help our clients be prepared.”